MDXG is undervalued compared to OSIR and generates more cash. Epifix is the moneymaker for MDXG. Grafix for OSIR.
OSIR soared on a Grafix study recently. But the buzz on the streets are that the sales force for MDXG are OUTSELLING the Grafix people. The market share for MDXG is coming from wound graft leaders such as Dermagraft and Apligraf. Anecdotal experience matters to physicians and Epifix is their choice.
Many will argue that Epifix is superior to Grafix. But it doesn't really matter at this point. Focus on the BIG PICTURE:
The diabetic ulcer market is worth 1-2 billion. That is where solutions are most needed immediately.
This is where MDXG and OSIR will thrive. There is room for both.